Tekla Life Sciences Investors (HQL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Tekla Life Sciences Investors, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Tekla Life Sciences Investors (HQL) has returned 0.18% so far this year and 45.72% over the past 12 months. Over the last ten years, HQL has returned 8.95% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 4, 1992, HQL's average daily return is +0.04%, while the average monthly return is +0.96%. At this rate, your investment would double in approximately 6.0 years.

Historically, 55% of months were positive and 45% were negative. The best month was Feb 2000 with a return of +64.7%, while the worst month was Aug 1998 at -24.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 4 months.

On a daily basis, HQL closed higher 49% of trading days. The best single day was Feb 17, 2000 with a return of +20.1%, while the worst single day was Apr 14, 2000 at -13.1%.

Tekla Life Sciences Investors has an annualized alpha of 3.53%, beta of 0.80, and R² of 0.30 versus S&P 500 Index. Calculated based on daily prices since May 05, 1992.

• This stock participated in 95.14% of S&P 500 Index downside but only 93.56% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.30 means the benchmark explains less than half of this stock's behavior — treat beta with caution or consider switching to a more representative benchmark.

HQL ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Tekla Life Sciences Investors (HQL) and compare them to a chosen benchmark (S&P 500 Index).

Tekla Life Sciences Investors provided a 11.74% dividend yield over the last twelve months, with an annual payout of $1.91 per share.

The table displays the monthly dividend distributions for Tekla Life Sciences Investors. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Tekla Life Sciences Investors. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Tekla Life Sciences Investors was 62.65%, occurring on Oct 9, 2002. Recovery took 2336 trading sessions.

The current Tekla Life Sciences Investors drawdown is 4.87%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Tekla Life Sciences Investors over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Tekla Life Sciences Investors is priced in the market compared to other companies in the Asset Management industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.